STAT Plus: Pharmalittle: Two more Alzheimer’s drugs fail in studies; how Democratic candidates differ on lowering drug costs
Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, because that oh-so-familiar routine of meetings, deadlines, and whatnot has predictably returned. To cope, we are undertaking what is surely a familiar ritual by now — brewing cups of stimulation to fire up the neurons. We need all the help we can get. Our choice today, by the way, is hazelnut creme, for those tracking this sort of thing. And now, here are a few tidbits to help you along. Hope your day is smashing and do stay in touch.
Experimental drugs from Roche (RHHBY) and Eli Lilly (LLY) failed to halt Alzheimer’s disease in their latest test in a blow to people whose genes make them particularly vulnerable to the illness, Reuters reports. The studies focused on rare autosomal dominant Alzheimer’s disease, which is caused by gene mutations that follow generations of families. A pair of separate Roche studies of its drug against a form of Alzheimer’s disease not directly caused by gene mutations would continue. It is due to produce results in 2022.
Continue to STAT Plus to read the full story…
